Top Page
CervoMed
(NASDAQ:CRVO)
CervoMed (CRVO) vs. SPDR S&P 500 ETF (SPY)
CervoMed Business Overview & Revenue Model
CervoMed Financial Statement Overview
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.01M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -28.29M | -18.23M | -7.81M | -5.80M | -15.94M |
| Net Income | -26.97M | -16.29M | -2.17M | -5.80M | -24.10M |
Balance Sheet | |||||
| Total Assets | 23.40M | 43.08M | 9.97M | 4.16M | 37.84M |
| Cash, Cash Equivalents and Short-Term Investments | 20.86M | 38.92M | 7.79M | 4.09M | 37.31M |
| Total Debt | 0.00 | 0.00 | 0.00 | 12.41M | 0.00 |
| Total Liabilities | 5.18M | 3.88M | 2.60M | 13.16M | 2.93M |
| Stockholders Equity | 18.22M | 39.20M | 7.38M | -9.00M | 34.91M |
Cash Flow | |||||
| Free Cash Flow | -23.45M | -16.53M | -7.45M | -2.57M | -14.50M |
| Operating Cash Flow | -23.45M | -16.53M | -7.45M | -2.57M | -14.50M |
| Investing Cash Flow | 18.10M | -28.66M | 0.00 | 0.00 | 4.00K |
| Financing Cash Flow | 4.59M | 46.40M | 11.15M | 0.00 | 33.30M |
CervoMed Technical Analysis
CervoMed Risk Analysis
CervoMed Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $188.38M | -2.24 | -129.98% | ― | 250.00% | 15.15% | |
52 Neutral | $34.42M | -0.53 | -191.12% | ― | ― | -24.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $389.14M | -2.14 | -115.27% | ― | 2925.73% | -294.29% | |
47 Neutral | $37.22M | -2.65 | -76.78% | ― | -38.81% | -76.96% | |
41 Neutral | $31.04M | -6.26 | -88.89% | ― | 56.52% | 75.22% |
CervoMed Corporate Events
On March 19, 2026, CervoMed reported new analyses from its Phase 2b RewinD-LB trial showing that DLB patients with lower plasma pTau181 levels, indicating absence of Alzheimer’s co-pathology and earlier-stage disease, experienced greater clinical benefit from neflamapimod. The data, to be presented March 21, 2026 at the AD/PD 2026 Conference, also demonstrate that a specific trough plasma concentration threshold is associated with clinical response, informing both patient enrichment and the 50mg TID dosing strategy for a planned Phase 3 trial.
Trial results showed that when patients switched from placebo to a reformulated neflamapimod capsule batch that reliably achieved target plasma levels, they had statistically significant and clinically meaningful slowing of disease progression, particularly in those with plasma pTau181 below 21 pg/mL. These findings strengthen CervoMed’s positioning in DLB by supporting a biomarker-driven Phase 3 design expected to enroll predominantly “pure” DLB patients without Alzheimer’s co-pathology, potentially increasing the likelihood of success and offering clearer value for future stakeholders if efficacy is confirmed.
The most recent analyst rating on (CRVO) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on CervoMed stock, see the CRVO Stock Forecast page.
On March 17, 2026, CervoMed reported fourth quarter and full-year 2025 results alongside updates on its neflamapimod pipeline, highlighting positive Phase 2b RewinD-LB data in dementia with Lewy bodies presented in 2025 and regulatory alignment with the FDA and other global agencies on a Phase 3 trial design. The company, which ended 2025 with $20.9 million in cash and a net loss of $27.0 million, plans to initiate a global Phase 3 DLB study and deliver multiple data readouts across stroke recovery, primary progressive aphasia and ALS in the second half of 2026, though these plans hinge on securing additional funding amid rising R&D and G&A expenses.
CervoMed also strengthened its position through issuance of new neflamapimod patents in Europe, Japan and China, the inclusion of the drug in the UK EXPERTS-ALS platform, and the hiring of a new chief commercial and business officer and a new board member in late 2025. Collectively, the clinical momentum, expanded intellectual property and upcoming catalysts underscore CervoMed’s bid to establish neflamapimod as a potential first-in-class therapy for multiple neurodegenerative indications, while its limited cash runway of roughly six months from the release date underscores financing risk for investors and partners.
The most recent analyst rating on (CRVO) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on CervoMed stock, see the CRVO Stock Forecast page.
On March 4, 2026, CervoMed reported completion of a Phase 1 healthy volunteer study assessing the pharmacokinetics of a new, stable crystal form of its lead drug neflamapimod, manufactured via a controlled process to avoid prior polymorph-related variability. The company said the new formulation’s bioavailability and pharmacokinetic profile largely overlap with the clinically active drug product used in the extension phase of the Phase 2b RewinD-LB trial.
Based on these data, CervoMed has selected a 50mg three-times-daily dosing regimen of the stable crystal form of neflamapimod for its planned Phase 3 dementia with Lewy bodies trial, aiming to match plasma drug levels associated with prior clinical and biomarker benefits. Management highlighted that resolving historical manufacturing and bioavailability issues is intended to position the Phase 3 program to reproduce the positive outcomes seen with the effective batch in RewinD-LB, a key step for the company’s late-stage development strategy in neurodegenerative disease.
The most recent analyst rating on (CRVO) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on CervoMed stock, see the CRVO Stock Forecast page.
CervoMed Inc., a U.S.-based clinical-stage biotechnology company listed on Nasdaq, develops oral small-molecule therapies for age-related neurodegenerative disorders, led by neflamapimod. The drug candidate targets p38 MAP kinase–mediated neuroinflammation and synaptic dysfunction, and has shown encouraging safety and efficacy signals in dementia with Lewy bodies and other brain disorders in early- and mid-stage trials.
On February 18, 2026, CervoMed announced that neflamapimod was selected for inclusion in the U.K. EXPERTS-ALS platform, a government- and charity-funded trial system designed to rapidly prioritize promising amyotrophic lateral sclerosis treatments. The NIHR-backed, Sheffield-sponsored trial will be the first to test neflamapimod in ALS, initially enrolling about 35 patients for 18–24 weeks with funding external to CervoMed, which could meaningfully expand the drug’s neurodegeneration footprint while the company continues to prioritize its planned Phase 3 dementia with Lewy bodies program.
Within EXPERTS-ALS, neflamapimod will be evaluated in a randomized, multicenter, open-label, multi-arm study using blood neurofilament light chain as the primary biomarker of neuroaxonal damage and disease activity. Positive data could justify expanding enrollment to as many as 80 patients and strengthen neflamapimod’s positioning as a potential disease-modifying therapy in ALS, offering upside for patients and investors if the biomarker and clinical readouts align with the drug’s prior translational and clinical results.
Academic experts cited neflamapimod’s ability to cross the blood–brain barrier, selectively inhibit p38, and its track record in dementia with Lewy bodies as key reasons for its inclusion in the platform. For CervoMed, participation in the fully funded U.K. platform provides a capital-efficient way to probe ALS while preserving resources for its core dementia program, potentially enhancing its strategic value in the competitive neurodegeneration drug-development landscape if the ALS data prove supportive.
The most recent analyst rating on (CRVO) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on CervoMed stock, see the CRVO Stock Forecast page.
On January 8, 2026, CervoMed Inc. disclosed that it has made an investor presentation available on its website under the “Investors – Events and Presentations” section, summarizing information about its business, clinical studies, development plans, financial position and related matters. The company noted that its representatives may periodically use this presentation, with possible non-material modifications, in conferences and investor meetings, emphasized that the materials should be considered in the context of its broader SEC filings and public announcements, and clarified that the furnished information is not deemed “filed” for purposes of the Exchange Act and does not carry the associated liability unless specifically incorporated by reference in future regulatory filings.
The most recent analyst rating on (CRVO) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on CervoMed stock, see the CRVO Stock Forecast page.